Nov 6 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q3 LOSS PER SHARE $1.06.Q3 EARNINGS PER SHARE VIEW $-1.33 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $1.6 MILLION VERSUS I/B/E/S VIEW $1.8 MILLION.UPDATED ITS EXPECTED FY 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $62 MILLION TO $64 MILLION.UPDATED EXPECTED FY 2018 GAAP SELLING, GENERAL AND ADMINISTRATIVE EXPENSES TO BE IN RANGE OF $77 MILLION TO $79 MILLION.
Full Article
April 6 (Reuters) - Cipher Pharmaceuticals::CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO U.S. FDA-APPROVED A-101 40% TOPICAL SOLUTION FROM ACLARIS THERAPEUTICS.CIPHER PHARMACEUTICALS INC - ACLARIS WILL RECEIVE AN UPFRONT PAYMENT OF US$1.0 MLN .
Full Article
March 19 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS.ACLARIS THERAPEUTICS INC - PRIMARY, SECONDARY, AND EXPLORATORY ENDPOINTS OF PHASE 2 TRIAL MET DURING 8-WEEK TREATMENT PERIOD.ACLARIS THERAPEUTICS - AFTER TREATMENT COMPLETED, GREATER IMPROVEMENT VERSUS. PLACEBO OBSERVED IN 3-MONTH POST-TREATMENT FOLLOW-UP EVALUATION IN TRIAL.ACLARIS THERAPEUTICS INC - THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AMONG SUBJECTS TREATED WITH A-101 45%.ACLARIS THERAPEUTICS INC - A-101 45% WAS GENERALLY WELL TOLERATED THROUGH VISIT 13.
Full Article
March 12 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q4 REVENUE $1.0 MILLION.Q4 REVENUE VIEW $520,000 -- THOMSON REUTERS I/B/E/S.AS OF DECEMBER 31, 2017, HAD AGGREGATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $208.9 MILLION.ACLARIS THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND OPERATIONS INTO H2 2019.
Full Article
Jan 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS - POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS.ACLARIS - A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS.
Full Article
Dec 15 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS - FDA APPROVAL OF ESKATA BASED ON 2 PIVOTAL PHASE 3 TRIALS THAT SHOWED SAFETY & EFFICACY OF ESKATA FOR TREATMENT OF RAISED SKS.
Full Article
Nov 7 (Reuters) - Aclaris Therapeutics Inc -:Aclaris Therapeutics reports third quarter 2017 financial results.Aclaris Therapeutics Inc - qtrly loss per share $0.63.Aclaris Therapeutics Inc - qtrly revenue of $684,000.Aclaris Therapeutics Inc- cash burn for 2017 is now estimated to be in range of $56 million to $59 million.Aclaris Therapeutics Inc- research and development expenses for 2017 are now estimated to be in range of $39 million to $42 million.
Full Article
Sept 19 (Reuters) - Aclaris Therapeutics Inc :Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101 topical solution for treatment of facial seborrheic keratosis.Aclaris Therapeutics Inc - in trial, A-101 achieved statistical significance in clearing SK lesions on face in a dose-related fashion.Aclaris Therapeutics Inc - FDA's Prescription Drug User Fee Act Action date for new drug application is December 24, 2017.Aclaris Therapeutics Inc - A-101 was well tolerated at both concentrations studied.Aclaris Therapeutics Inc - there were no treatment-related adverse events among patients treated with A-101.
Full Article
Aug 14 (Reuters) - Aclaris Therapeutics Inc :Vivo Ventures VII LLC reports 9.5 percent stake in Aclaris Therapeutics Inc as of March 15, 2017 - SEC filing.Vivo Ventures VII LLC had previously reported 13.34 percent in Aclaris Therapeutics Inc as of February 28, 2017.
Full Article
Aug 10 (Reuters) - Aclaris Therapeutics Inc -:Aclaris announces pricing of public offering of common stock.Announces public offering of 3.26 million units at a public offering price of $23.02 per common unit.
Full Article
Earnings vs. 
Estimates